Novavax’s COVID-19 vaccine is highly effective -- 90.4% effective overall -- and protects against coronavirus variants, the company announced Monday.
Novavax intends to file for authorizations from the FDA and European agencies in September and plans to produce 100 million doses per month by that time, according to the news release. More analyses will be submitted to peer-reviewed journals for publication. The company is also beginning to test the vaccine in ages 12-18.
The vaccine, which can be stored in regular refrigerators and is easy to transport, is expected to play a major role in vaccine supply worldwide, the AP reported. More than half of the U.S. population has received at least one vaccine dose, but less than 1% of people in developing countries have gotten a vaccine. Novavax has committed to supply the U.S. with 110 million doses during the next year and 1.1 billion doses to developing countries.
“Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Erck told the AP. In the U.S., the Novavax shots could also be effective boosters to protect against emerging variants and waning
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate for doses. While demand for COVID-19 shots in the U.S. has dropped off dramatically and the country has more than enough doses to go around, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world.
Read more »
Novavax vaccine over 90% effective in protecting against COVID-19 infection, study showsNovavax expects to request federal authorization for its vaccine this summer after it completes final chemistry, manufacturing and control requirements.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico
Read more »